Clinical Trial Update: Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of Diabetes

View source ↗

Summary

This completed observational study assessed the efficacy and safety of NovoMix 30 in diabetes patients, including type 1 and type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• NovoMix 30 (insulin aspart protamine fixed-dose combination)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 1 | Status: COMPLETED